<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857453</url>
  </required_header>
  <id_info>
    <org_study_id>2012-002803-16</org_study_id>
    <nct_id>NCT01857453</nct_id>
  </id_info>
  <brief_title>Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas</brief_title>
  <acronym>RSMA2010</acronym>
  <official_title>National, Multicentric, Prospective Phase II Study Estimating the Interest of a Dose Decrease for Radiation Therapy Associated With a Carboplatine and Etoposide Based Chemotherapy for the Treatment of Standard Risk Adult Medulloblastomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Paul Strauss</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Colmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult medulloblastoma is a rare tumour.

      The &quot;standard risk &quot; group (complete surgery or residual tumour lower than 1,5 cm2, absence
      of malignant cells in the cerebrospinal fluid, absence of metastasis, absence of MYC
      amplification and exclusion of large cells medulloblastoma) concerns, for the adult
      population, a majority of patients at diagnosis (about ¾ of cases).

      Conventional treatment is classically based on a 54/36 Gy cranio-spinal radiotherapy (54 Gy
      on the posterior fossa and 36 Gy on the nevraxis).

      This treatment is associated with an acute toxicity (haematological, cutaneous, digestive and
      general) wich decreases gradually when patient goes away from the treatment period.

      For this category of patients and this modality of treatment, The French intergroup
      experience, pleads in favour of a late and progressive neurotoxicity.

      This neurotoxicity is associated with a clear degradation of the quality of life.

      In the light of paediatric studies :

      We propose a phase II study to estimate the interest of a decrease of radiation doses
      compensated by a chemotherapy according to the following schedule

        1. carboplatine + etoposide based chemotherapy every 28 days x 2

        2. followed by, less than 80 days after the surgery, radiation therapy with 24 Gy on the in
           toto neuro axis and 54 Gy on the post operative bed.

      The majority of French centres concerned with the neuro-oncology are involved in this trial.

      About 25 new cases by year are waited. A centralized analysis of pathological slides and of
      the pre and post surgery Magnetic Resonance Imaging is foreseen.

      The main objective is to estimate the survival without disease at 1 year

      Secondary objectives associate the evaluations of the rate of complete response at the end of
      procedure, the overall survival, the survival without disease, the survival without events,
      the neurocognitiv toxicity, the endocrine toxicity, the hearing toxicity and the time until
      definitive deterioration of the quality of life Associated studies

      Two associated studies are besides foreseen (parallel search for co-financing):

        1. A biologic study is planed with the aim to confirm, by morphological, genomic and
           transcriptomic studies, the interest, for the adult population, of the prognostic
           markers used in paediatric population

        2. A radiological study is planed with the aim to estimate the interest :

             -  of a multimodal follow-up (spectroscopy and perfusion imaging) for the premature
                detection of recurrences

             -  of the study of functional connectivity in correlation with the neuropsychological
                follow-up for the analysis of the aetiology and premature markers of neurotoxicity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival without disease at 1 year</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Medulloblastoma</condition>
  <arm_group>
    <arm_group_label>teatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatine</intervention_name>
    <description>carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed</description>
    <arm_group_label>teatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed</description>
    <arm_group_label>teatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed</description>
    <arm_group_label>teatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic diagnosis of medulloblastoma expect large cells type

          -  Patients between 18 and 70 years

          -  Résidual tumor les than 1.5 square centimeter (greater diameter)

          -  No sus tentorial or spinal location

          -  Absence of tumoral cells in the cerebrospinal fluid taken before, during or 14 days
             after surgery

          -  Absence of MYC amplification

          -  AID, B and C hepatitis positive serologies

          -  Negative βHCG dosage and effective contraception for potentially pregnant women

          -  Writed consent obtain

        Exclusion Criteria:

          -  Age &lt; 18 or &gt; 70 years

          -  Previous diagnosis of medulloblastoma

          -  Previous treatment with chemotherapy

          -  Previous cranial or spinal radiation therapy

          -  Carboplatinum or etoposide contraindication

          -  Previous cancer in the five years before the inclusion except basocellular carcinoma
             of the skin and in situ cancer of the uterine cervix

          -  Severe renal renal insufficiency with a creatinine clearance &lt; 60 ml/min

          -  Liver insufficiency with a contraindication of carboplatinum or etoposide based
             chemotherapy or elevated transaminases &gt; 3N.

          -  Insufficient haematopoetic reserve (thrombocytes &lt; 100 000/mm3 ou neutrophil
             polynuclear &lt; 1500/mm3)

          -  Previous organ transplantation or immunosuppression

          -  Pregnant women or women without contraception

          -  Incapacity of respecting the recommanded follow up

          -  Participation in another therapeutic clinical trial

          -  Patient under custody

          -  Not social security regime membership
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc TAILLANDIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU NANCY - France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luc TAILLANDIER</last_name>
    <phone>+33 3 83 85 16 88</phone>
    <email>l.taillandier@chu-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte CARNIN</last_name>
    <phone>+33 3 83 85 95 92</phone>
    <email>c.carnin@chu-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80053</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu BOONE</last_name>
      <email>Boone.Mathieu@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle CATRY THOMAS</last_name>
      <email>isabelle.catry-thomas@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Sebastien GUILLAMO</last_name>
      <email>guillamo-js@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jimmy VOIRIN</last_name>
      <email>jimmy.voirin@ch-colmar.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cenre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronique LORGIS</last_name>
      <email>vlorgis@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie LE RHUN</last_name>
      <email>emilie.lerhun@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berrard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Pierre SUNYACH</last_name>
      <email>marie-pierre.sunyach@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maryline BARRIE</last_name>
      <email>mbarrie@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine KERR</last_name>
      <email>Christine.Kerr@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc TAILLANDIER</last_name>
      <phone>+33 3 83 85 16 88</phone>
      <email>l.taillandier@chu-nancy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte CARNIN</last_name>
      <phone>+33 3 83 85 95 92</phone>
      <email>c.carnin@chu-nancy.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre René Ganducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Sebastien FRENEL</last_name>
      <phone>02.40.67.97.14</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine LEBRUN FRENAY</last_name>
      <email>lebrun.c@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chantal CAMPELLO</last_name>
      <email>chantal.campello@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire ALAPETITE</last_name>
      <email>claire.alapetite@curie.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP HP Groupe Hospitalier Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence LAIGLE DONADEY</last_name>
      <email>florence.laigle-donadey@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer COURLANCY</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe COLIN</last_name>
      <email>pcolin@iccreims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elodie VAULEON</last_name>
      <email>E.Vauleon@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georges NOEL</last_name>
      <email>GNoel@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra BENOUAICH AMIEL</last_name>
      <email>benouaich-amiel.a@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric DHERMAIN</last_name>
      <email>dhermain@igr.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult Patients Medulloblatoma Standard risk group Chemotherapy Radiotherapy Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

